Polymorphism of Pro12Ala in the peroxisome proliferator-activated receptor 2 gene in Iranian diabetic and obese subjects

Metabolic Syndrome and Related Disorders

Volumn 7, Issue 5, 2009, Pages 453-458

  Mirzaei, Hassan ^a,b   Akrami, Seyed Mohammad ^b   Golmohammadi, Taghi ^b   Doosti, Mahmood ^b   Heshmat, Ramin ^b   Nakhjavani, Manouchehr ^b   Amiri, Parvin ^b  

^a GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2;

ADULT; AGED; ALLELE; ARTICLE; BODY MASS; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ALANINE; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IRAN; LOGISTIC MODELS; MALE; OBESITY; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA; PROLINE; RISK ASSESSMENT; RISK FACTORS;

EID: 70350303944     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2008.0099     Document Type: Article

References (47)

1. Kersten S. Peroxisome proliferator-activated receptors and obesity. Eur J Pharm 2002;440:223-234.
2. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPAR gamma 2: Tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994;8:1224-1234.
3. Ray DM, Spinelli SL, O'Brien JJ, Blumberg N, Phipps RP. Platelets as a novel target for PPARgamma ligands: implications for inflammation, diabetes, and cardiovascular disease. BioDrugs 2006;20:231-241.
4. Lemberger T, Desvergne B, Wahli W. Peroxisome proliferatoractivated receptors: A nuclear receptor signaling pathway in lipid physiology. Endocr Rev 1996;12:335-363.
5. Vidal-Puig A, Jimenez-Linan M, Lowell BB, Hamann A, Hu E, Spiegelman B et al. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J Clin Invest 1996;97:2553-2561.
6. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 1997;241:270-274
7. Fakhrzadeh H, Ghotbi S, Pourebrahim R, Nouri M, Heshmat R, Bandarian F et al. Total plasma homocysteine, folate, and vitamin B12 status in healthy Iranian adults: The Tehran homocysteine survey (2003-2004): A cross-sectional population based study. BMC Public Health 2006;6:29.
8. Fakhrzadeh H, Ghotbi S, Pourebrahim R, Heshmat R, Nouri M, Shafaee A, et al. Plasma homocysteine concentration and blood pressure in healthy Iranian adults: The Tehran Homocysteine Survey (2003-2004). J Hum Hypertens 2005;19:869-876. (Pubitemid 41637603)
9. Miller S, Dykes D, Polesky H. Simple salting out procedure for extracting DNA from nucleated cells. Nucleic Acids Res 1988;16:1215.
10. Oh EY, Min K, Chung JH, Min YK, Lee MS, Kim KW et al. Significance of Pro12Ala mutation in peroxisome proliferatoractivated receptor-gamma2 in Korean diabetic and obese subjects. J Clin Endocrinol Metab 2000;85:1801-1804.
11. Tai E, Corella D, Yap MD, Adiconis X, Chew SK, Tan C et al. Differential effects of the C1431T and Pro12Ala PPARgamma gene variants on plasma lipids and diabetes risk in an Asian population. J Lipid Res 2004;45:674-685.
12. Mori Y, Motoyama H, Katakura T, Yasuda K, Kadowaki H, Beamer BA et al. Effect of the Pro12Ala variant of the human peroxisome proliferator-activated receptor gamma 2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men. Biochem Biophys Res Commun 1998;251:195-198.
13. Danawati CW, Nagata M, Moriyama H, Hara K, Yasuda H, Nakayama M et al. A possible association of Pro12Ala polymorphism in peroxisome proliferators- activated receptor ã2 gene with obesity in native Javanese in Indonesia. Diabetes Metab Res Rev 2005;21:465-469.
14. Frederiksen L, Brodbaek K, Fenger M, Jorgensen T, Borch- Johnsen K et al. Comment: Studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: Homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab 2002;87:3989-3992.
15. Muller Y, Bogardus C, Beamer B, Shuldiner A, Baier L. A functional variant in the peroxisome proliferator-activated receptor gamma2 promoter is associated with predictors of obesity and type 2 diabetes in Pima Indians. Diabetes 2003;52:1864-1871.
16. Kolehmainen M, Uusitupa MI, Alhava E, Laakso M, Vidal H. Effect of the Pro12Ala polymorphism in the peroxisome proliferator- activated receptor (PPAR) gamma2 gene on the expression of PPARgamma target genes in adipose tissue of massively obese subjects. J Clin Endocrinol Metab 2003;88:1717-1722.
17. Pinterova D, Cerna M, Kolostova K. The frequency of alleles of the Pro 12 Ala polymorphism in PPAAR-gamma2 is different between healthy controls and patients with type 2 diabetes. Folia Biologica 2004;50:153-156.
18. Ghoussaini M, Meyre D, Lobbens S, Charpentier G, Clement K, Charles M et al. Implication of the Pro12Ala Polymorphism of the PPAR-gamma 2 Gene in type II diabetes and obesity in the French population. BMC Med Gen 2005;6:11.
19. Beamer BA, Yen CJ, Andersen RE, Muller D, Elahi D, Cheskin J et al. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes 1998;47:1806-1808.
20. Sanchez J, Serrano Rios M, Fernandez P, Laakso M, Larrad MT. Effect of the Pro12Ala polymorphism of the peroxisome proliferator- activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish Population. Eur J Endocrinol 2002;47:495-501.
21. Hasstedt S, Ren Q, Teng K, Elebein S. Effect of the peroxisome proliferator-activated receptor-gamma 2 Pro(12)Ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type II diabetic kindreds. J Clin Endocrinol Metab 2001;86:536-541.
22. Stumvoll M, Häring H. The peroxisome proliferator-activated receptor gamma 2 Pro12Ala Polymorphism. Diabetes 2002;51:2341-2347.
23. Stumvoll M, Wahl HG, Löblein K, Becker R, Machicao F, Jacob S et al.The Pro12Ala polymorphism in the peroxisome proliferator -activated receptor-ã2 gene is associated with increased antilipolytic insulin sensitivity. Diabetes 2001;50:876-881.
24. Ristow M, Muller Wieland D, Pfeiffer A, Krone W, Kahn CR. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 1998;339:953-959.
25. Nelson TL, Fingerlin TE, Moss L, Barmada MM, Ferrell RE, Norris JM. The PPARgamma Pro12Ala polymorphism is not associated with body mass index or waist circumference among Hispanics from Colorado. Ann Nutr Metab 2007;51:252-257.
26. Nelson TL, Fingerlin TE, Moss L, Barmada MM, Ferrell RE, Norris JM. The peroxisome proliferator-activated receptor gamma coactivator-1 alpha gene (PGC-1alpha) is not associated with type 2 diabetes mellitus or body mass index among Hispanic and non Hispanic Whites from Colorado. Exp. Clin Endocrinol Diabetes 2007;115:268-275.
27. Mancini F, Vaccaro O, Sabatino L, Tufano A, Rivellese A, Riccardi G et al. Pro12Ala substitution in the peroxisome proliferator- activated receptor-gamma2 is not associated with type 2 diabetes. Diabetes 1999;48:1466-1468.
28. Zietz B, Barth N, Spiegel D, Schmitz G, Scholmerich J, SchaZer A. Pro12Ala polymorphism in the peroxisome proliferatoractivated receptor-gamma2 (PPAR ã2) is associated with higher levels of total cholesterol and LDL-cholesterol in male caucasian type 2 diabetes patients. Exp Clin Endocrinol Diabetes 2002;110:60-66.
29. Clement K, Hercberg S, Passinge B, Galan P, Varroud-Vial M, Shuldiner AR et al. The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type II diabetes. Int J Obes Relat Metab Disord 2000;24:391-393.
30. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Auwerx J, Deeb S et al. Impact of the peroxisome proliferator activated Receptor gamma2 Pro12Ala polymorphism on adiposity, lipids and noninsulin- dependent diabetes mellitus. Int J Obes Relat Metab Disord 2000;24:195-199.
31. Malecki M, Frey J, Klupa T, Skupien J, Walus M, Mlynarski W et al. Pro12Ala polymorphism of PPARgamma2 gene and susceptibility to type 2 diabetes mellitus in a Polish population. Diabetes Res Clin Pract 2003;62:105-111. (Pubitemid 37315885)
32. Wakil SM, Al-Rubeaan K, Alsmadi O, Imtiaz F, Carroll P, Rajab M et al. The peroxisome proliferator-activated Receptor-ã2 P12A polymorphism and type 2 diabetes in an Arab population. Diabetes Care 2006;29:171-172.
33. Li LL, Ma XL, Ran JX, Sun XF, Xu LM, Ren J et al. Genetic polymorphism of peroxisome proliferator-activated receptor-ã2 Pro12Ala on ethnic susceptibility to diabetes in uygur, kazak and han subjects. Clin Exp Pharmacol Physiol 2008;35:187-191.
34. Stefanski A, Majkowska L, Ciechanowicz A, Frankow M, Safranow K, Parczewski M et al. Lack of Association between the Pro12Ala Polymorphism in PPAR-ã2 gene and body weight changes, insulin resistance and chronic diabetic complications in obese patients with type 2 diabetes. Arch Med Res 2006;37:736-743.
35. Altshuler D, Hirschhorn J, Klannemark M, Lindgren CM, Vohl MC, Nemesh J et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000;26:76-80.
36. Meshkani R, Taghikhani M, Larijani B, Bahrami Y, Khatami S, Khoshbin E et al. Pro12Ala polymorphism of the peroxisome proliferatoractivated receptor-[gamma)2 (PPAR[gamma)-2) gene is associated with greater insulin sensitivity and decreased risk of type 2 diabetes in an Iranian population. Clin Chem Lab Med 2007;45:477-482.
37. Douglas J, Erdos M, Watanabe R, Braun A, Johnston CL, Oeth P et al. The peroxisome proliferator-activated receptor-ã2 Pro12A1a variant: Association with type II diabetes and trait differences. Diabetes 2001;50:886-890.
38. Ludovico O, Pellegrini F, Di Paola R, Minenna A, Mastroianno S, Cardellini M et al. Heterogeneous effect of peroxisome proliferator- activated receptor gamma2 Ala12 variant on type diabetes risk. Obesity (Silver Spring) 2007;15:1076-1081.
39. Boden G., Free fatty acids, insulin resistance, and type 2 diabetes mellitus. Proc Assoc Am Physicians 1999;111:241-248. (Pubitemid 29240904)
40. Masud S, Ye S. Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: A meta-analysis. J Med Genet 2003;40:773-780.
41. Cole S, Mitchell B, Hsueh W, Pineda P, Beamer BA, Shuldiner AR, et al. The Pro12Ala variant of peroxisome proliferator-activated receptorgamma2 (PPAR-gamma2) is associated with measures of obesity in Mexican Americans. Int J Obes Relat Metab Disord 2000;24:522-524.
42. Doney A, Fischer B, Cecil J, Boylan K, McGuigan FE, Ralston SH, et al. Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to type 2 diabetes. Diabetologia 2004;47:555-558.
43. Pihlajamaki J, Miettinen R, Valve R, Karjalainen L, Mykkanen L, Kuusisto J et al. The Pro12A1a substitution in the peroxisome proliferator activated receptor gamma 2 is associated with an insulin-sensitive phenotype in families with familial combined hyperlipidemia and in nondiabetic elderly subjects with dyslipidemia. Atherosclerosis 2000;151:567-574.
44. Ringel J, Engeli S, Distler A, Sharma AM. Pro12Ala missense mutation of the peroxisome proliferator activated receptor gamma and diabetes mellitus. Biochem Biophys Res Commun 1999;254:450-453.
45. Luan J, Browne PO, Harding AH, Halsall DJ, O'Rahilly S, Chatterjee VK, Wareham NJ. Evidence for genenutrient interaction at the PPARgamma locus. Diabetes 2001;50:686-689.
46. Scacchi R, Pinto A, Rickards O, Pacella A, De Stefano GF, Cannella C et al. An analysis of peroxisome proliferator-activated receptor gamma (PPAR-ã2) Pro12Ala polymorphism distribution and prevalence of type 2 diabetes mellitus (T2DM) in world populations in relation to dietary habits. Nutr Metab Cardiovasc Dis 2007;17:632-641.
47. Florez JC. Phenotypic consequences of the peroxisome proliferators activated receptor-gamma Pro12Ala polymorphism: The weight of the evidence in genetic association studies. J Clin Endocrinol Metab 2004;89:4234-4237.